\r\n<\/a>\r\n<\/p>\n<\/div><\/section><\/div> <\/p>\n<\/div><\/section> <\/p>\n MammaTyper\u00ae<\/sup> is the first real innovation in subtyping breast cancer in decades. Using RT-qPCR technology proven during the COVID-19 pandemic, the multigene test works through an easily replicated and quantitative measurement of marker gene expression, classifying each sample as a St. Gallen molecular subtype. MammaTyper\u00ae<\/sup> provides standardised, objective results and can also accurately assess HER2-low tumours and Ki-67 markers, offering a reliable basis for selecting the best treatment option for patients.<\/p>\n By being robustly reproducible, it avoids many of the common pre-analytical errors in the pathology laboratory, especially for the proliferation marker Ki-67 \u2013 critical in luminal subtyping and prognosis. Using MammaTyper\u00ae\u00a0to subtype breast cancer tissue is a valuable resource for pathologists and can provide the reassurance with accurate subtyping for tailored treatment which are patient-specific.<\/p>\n By sharing deep scientific knowledge and an understanding of clinical needs, Sysmex Life Science and Cerca Biotech will work closely together to enable individualised breast cancer diagnostics across many markets.<\/p>\n<\/div><\/section> \u201cRepeatable, reproducible testing is the only way we can ensure that every person diagnosed with breast cancer can access the best treatment for their individual case.\u00a0Through this partnership with Sysmex\u00a0Europe,\u00a0MammaTyper\u00ae<\/sup> will be available as a valuable diagnostic tool to more pathologists in more markets across Europe. We are proud that MammaTyper\u00ae<\/sup>will be part of Sysmex\u2019s cutting-edge portfolio.\u201d<\/p>\n \u201cWe are excited to be collaborating with\u00a0Cerca\u00a0Biotech and\u00a0to extend\u00a0and strengthen\u00a0our\u00a0innovative\u00a0molecular portfolio,\u00a0building on the success of our\u00a0OSNA\u00ae<\/sup> solution in breast cancer. Considering the clinical need for accurate and individualised diagnostics, the MammaTyper\u00ae<\/sup> can play a key role in the breast cancer diagnostic pathway, providing guidance for the right treatment, thus improving the quality of life of patients.\u201d<\/p>\n For more information, visit\u00a0www.sysmex-europe.com<\/a>.<\/p>\n<\/div><\/section> MammaTyper kits<\/em><\/p>\n<\/div><\/section> <\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":" As a result of the agreement,\u00a0MammaTyper\u00ae\u00a0will become part of the Sysmex Life Science portfolio in 13 territories across EMEA, including the UK, Ireland and the majority of mainland Europe.<\/p>\n","protected":false},"author":3,"featured_media":19349,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19346"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=19346"}],"version-history":[{"count":9,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19346\/revisions"}],"predecessor-version":[{"id":19359,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19346\/revisions\/19359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/19349"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=19346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=19346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=19346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nSysmex Europe SE has signed a multi-market EMEA distribution agreement with Cerca Biotech, the company behind the innovative breast cancer diagnostic assay \u2013 MammaTyper\u00ae<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n
\nAs a result of the agreement,\u00a0MammaTyper\u00ae\u00a0<\/sup>will become part of the Sysmex Life Science portfolio in 13 territories across EMEA, including the UK, Ireland and the majority of mainland Europe.<\/h3>\n
\n
\nRichard Hughes, Director at Cerca Biotech:\u00a0<\/strong><\/h4>\n
Samantha Giangregorio, Head of Life Science, Vice President Sysmex Europe SE:\u00a0<\/strong><\/h4>\n
\n
\n
\nShare this<\/h5>